Bristol-myers Squibb Stock News

Bristol Myers Squibb press release (BMY): Q4 Non-GAAP EPS of $1.83 beats by $0.03.

Joe Biden is redoubling his efforts to fight cancer with a new "cancer cabinet." Here are the biotech stocks to buy that can benefit.

Shares of Bristol-Myers Squibb Co (NYSE: BMY) jumped 3.0% on Friday morning after the pharmaceutical giant reported its Q4 results and offered guidance for fiscal 2022. Q4 financial performance Bristo

Bristol Myers (BMY) delivered earnings and revenue surprises of 0% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb & Co  BMY has posted Q4 revenues of $11.98 billion, an increase of 8%, missing the consensus estimate of $12.08 billion.  Get the Inside Access Traders Are Using to Profit More

Shares of Bristol Myers Squibb Co. BMY, -1.13% were up 1.1% in premarket trading on Friday after the drug maker beat earnings expectations for the final quarter of the year. Bristol had earnings of $2

Drugmaker Bristol Myers Squibb Co on Friday posted slightly better than expected fourth-quarter earnings on strong sales of blood thinner Eliquis and cancer drug Opdivo.

Let us take a look at three biotech/pharma companies ??? BMY, REGN and SNY?

The BRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE (BMS PAC) successfully filed their F3XN MONTHLY YEAR-END with the coverage period of 12/01/2021 to 12/31/2021 and a confirmation ID of FEC-1564602 *********CommitteeId: C00035675 | FilingId: 1564602 | FormType: F3XN | CoverageFrom: 12/01/2021 | CoverageThrough: 12/31/2021 | ReportType: MONTHLY YEAR-END*********

Key Events This Week: ECB, BOE, Payrolls, Euro CPI And Earnings Galore It''s a relatively busy week with several key central bank announcements, notably from the ECB and BOE, as well as European CPI updates and the US payrolls report on Friday. Starting with the ECB, Deutsche Bank economists now expect a policy rate liftoff in December 2022 of 25bps, a view apparently shared by the market this morning. Theyre also anticipating a faster pace of tightening, with 25bp hikes in the deposit rate per quarter from December 2022, until rates reach +0.5% in September 2023. In terms of what it means for this February meeting, they write in their preview that they expect the slow, step-by-step pivot to exit will continue. Their view is that President Lagarde will reiterate the ECBs capacity to act once the inflation criteria in the rates guidance are met, whilst at the same time differentiating the needs of the Euro Area from the US. The other central bank decision that day is from the Bank of England, where expectations are for the BoE to follow up their December rate hike with another 25bps increase, taking the Bank Rate to 0.5%.

Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.

US Futures Start The Week With More Wild Swing In Another Volatile, Illiquid Session After a rollercoaster week that ended just barely higher following a late meltup on Friday, overnight volatile US stock futures swung to start the week, with Nasdaq 100 futures leading gains after rallying on Friday, before turning red and threatening to fizzle a global equity rally amid persistent worries over the Federal Reserve’s plan to hike interest rates this year. Emini S&P futures were down 0.5% or 21 points to 4401, after rising as high as 4437 and dropping as low as 4395 in another extremely illiquid session where China being offline for the week due to Lunar New Year did not help; Nasdaq futures were down 0.1% while Dow futures were lower 0.7%. Technology stocks led gains on the Stoxx Europe 600. Meanwhile, the dollar fell and oil rallied. As investors reconcile to a hawkish U.S. central bank coupled with strong earnings, the expensive parts of the U.S. stock market are undergoing a valuation re-rating along with the bond markets.

Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.

Biotech's blue bloods are the best bets in the space right now.

My Top Dividend Stocks For 2022